Wendy Kohrt
Concepts (666)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Density | 45 | 2024 | 482 | 6.540 |
Why?
| | Exercise | 68 | 2024 | 2201 | 4.720 |
Why?
| | Body Composition | 54 | 2024 | 706 | 4.300 |
Why?
| | Bone and Bones | 16 | 2021 | 315 | 3.270 |
Why?
| | Parathyroid Hormone | 9 | 2021 | 112 | 3.110 |
Why?
| | Postmenopause | 31 | 2020 | 391 | 3.070 |
Why?
| | Menopause | 13 | 2022 | 320 | 2.800 |
Why?
| | Estrogens | 21 | 2024 | 380 | 2.790 |
Why?
| | Bone Resorption | 7 | 2022 | 80 | 2.520 |
Why?
| | Estradiol | 18 | 2024 | 533 | 2.500 |
Why?
| | Calcium | 7 | 2021 | 1184 | 2.160 |
Why?
| | Premenopause | 11 | 2020 | 123 | 2.110 |
Why?
| | Estrogen Replacement Therapy | 16 | 2019 | 144 | 2.070 |
Why?
| | Gonadotropin-Releasing Hormone | 9 | 2024 | 212 | 2.010 |
Why?
| | Exercise Therapy | 19 | 2025 | 473 | 2.010 |
Why?
| | Energy Metabolism | 16 | 2024 | 936 | 1.850 |
Why?
| | Endothelium, Vascular | 12 | 2026 | 965 | 1.840 |
Why?
| | Estrogens, Conjugated (USP) | 9 | 2017 | 52 | 1.730 |
Why?
| | Glucose | 14 | 2025 | 1049 | 1.710 |
Why?
| | Walking | 11 | 2021 | 545 | 1.710 |
Why?
| | Collagen Type I | 13 | 2021 | 147 | 1.700 |
Why?
| | Parkinson Disease | 16 | 2025 | 600 | 1.660 |
Why?
| | Resistance Training | 9 | 2024 | 182 | 1.650 |
Why?
| | Trigger Points | 3 | 2025 | 15 | 1.560 |
Why?
| | Calcium, Dietary | 7 | 2017 | 53 | 1.550 |
Why?
| | Tension-Type Headache | 2 | 2025 | 11 | 1.480 |
Why?
| | Middle Aged | 130 | 2026 | 35928 | 1.390 |
Why?
| | Lactic Acid | 8 | 2025 | 302 | 1.380 |
Why?
| | Adipose Tissue | 25 | 2022 | 653 | 1.360 |
Why?
| | Dehydroepiandrosterone | 5 | 2018 | 50 | 1.360 |
Why?
| | Osteoporosis, Postmenopausal | 9 | 2019 | 40 | 1.360 |
Why?
| | Aging | 30 | 2026 | 1966 | 1.350 |
Why?
| | Lumbar Vertebrae | 11 | 2021 | 252 | 1.340 |
Why?
| | Femur Neck | 8 | 2020 | 62 | 1.330 |
Why?
| | Aged | 115 | 2026 | 25947 | 1.240 |
Why?
| | Female | 182 | 2025 | 78376 | 1.230 |
Why?
| | Ovary | 4 | 2024 | 228 | 1.210 |
Why?
| | Insulin | 26 | 2022 | 2507 | 1.200 |
Why?
| | Peptides | 12 | 2021 | 998 | 1.160 |
Why?
| | Bicycling | 9 | 2014 | 120 | 1.140 |
Why?
| | Homeostasis | 7 | 2019 | 640 | 1.130 |
Why?
| | Humans | 237 | 2026 | 144957 | 1.130 |
Why?
| | Hormone Replacement Therapy | 9 | 2018 | 106 | 1.120 |
Why?
| | Lipolysis | 6 | 2014 | 46 | 1.100 |
Why?
| | Cardiovascular Diseases | 14 | 2024 | 2171 | 1.090 |
Why?
| | Superficial Back Muscles | 3 | 2025 | 16 | 1.080 |
Why?
| | Muscle, Skeletal | 18 | 2025 | 1796 | 1.060 |
Why?
| | Oxygen Consumption | 32 | 2025 | 724 | 1.030 |
Why?
| | Obesity | 21 | 2024 | 3082 | 0.980 |
Why?
| | Absorptiometry, Photon | 19 | 2024 | 276 | 0.980 |
Why?
| | Testosterone | 9 | 2026 | 419 | 0.950 |
Why?
| | Arthroplasty, Replacement, Knee | 9 | 2017 | 372 | 0.940 |
Why?
| | Sleep Deprivation | 5 | 2022 | 206 | 0.920 |
Why?
| | Adipocytes | 6 | 2025 | 223 | 0.910 |
Why?
| | Adiposity | 5 | 2018 | 543 | 0.910 |
Why?
| | Vascular Stiffness | 6 | 2024 | 487 | 0.910 |
Why?
| | Vasodilation | 9 | 2025 | 523 | 0.900 |
Why?
| | Physical Endurance | 19 | 2015 | 278 | 0.870 |
Why?
| | Motor Activity | 11 | 2015 | 722 | 0.860 |
Why?
| | Follicle Stimulating Hormone | 6 | 2024 | 249 | 0.850 |
Why?
| | Insulin Resistance | 12 | 2025 | 1241 | 0.850 |
Why?
| | Sleep | 7 | 2022 | 901 | 0.840 |
Why?
| | Adult | 91 | 2026 | 40506 | 0.830 |
Why?
| | Male | 134 | 2026 | 72406 | 0.820 |
Why?
| | Quadriceps Muscle | 5 | 2017 | 118 | 0.820 |
Why?
| | Frail Elderly | 6 | 2013 | 134 | 0.820 |
Why?
| | Muscle Strength | 9 | 2024 | 330 | 0.810 |
Why?
| | Weight Loss | 11 | 2024 | 837 | 0.800 |
Why?
| | Dehydroepiandrosterone Sulfate | 4 | 2013 | 42 | 0.770 |
Why?
| | Sweating | 2 | 2019 | 41 | 0.750 |
Why?
| | Glycerol | 8 | 2013 | 90 | 0.730 |
Why?
| | Hypothalamo-Hypophyseal System | 3 | 2018 | 198 | 0.710 |
Why?
| | Regional Blood Flow | 4 | 2025 | 514 | 0.700 |
Why?
| | Pituitary-Adrenal System | 2 | 2018 | 165 | 0.700 |
Why?
| | Leptin | 8 | 2025 | 245 | 0.700 |
Why?
| | Double-Blind Method | 13 | 2018 | 2029 | 0.700 |
Why?
| | Electric Stimulation Therapy | 2 | 2012 | 63 | 0.690 |
Why?
| | Brachial Artery | 8 | 2025 | 206 | 0.680 |
Why?
| | Bone Remodeling | 6 | 2022 | 71 | 0.660 |
Why?
| | Weight-Bearing | 7 | 2017 | 181 | 0.660 |
Why?
| | Raloxifene Hydrochloride | 3 | 2017 | 15 | 0.660 |
Why?
| | Subcutaneous Fat | 3 | 2014 | 78 | 0.650 |
Why?
| | Exercise Test | 18 | 2024 | 634 | 0.610 |
Why?
| | Sex Factors | 10 | 2024 | 2114 | 0.610 |
Why?
| | Osteoarthritis, Knee | 6 | 2018 | 279 | 0.600 |
Why?
| | Skin | 4 | 2019 | 758 | 0.600 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 2018 | 72 | 0.590 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2021 | 338 | 0.580 |
Why?
| | Activities of Daily Living | 7 | 2020 | 441 | 0.570 |
Why?
| | Osteoporosis | 10 | 2024 | 236 | 0.560 |
Why?
| | Headache Disorders | 1 | 2018 | 19 | 0.560 |
Why?
| | Physical Fitness | 9 | 2014 | 209 | 0.560 |
Why?
| | Adaptation, Physiological | 4 | 2012 | 570 | 0.550 |
Why?
| | Massage | 1 | 2018 | 42 | 0.540 |
Why?
| | Heart Rate | 20 | 2025 | 855 | 0.540 |
Why?
| | Randomized Controlled Trials as Topic | 9 | 2024 | 1721 | 0.530 |
Why?
| | Biomarkers | 16 | 2025 | 4275 | 0.530 |
Why?
| | Weight Gain | 3 | 2011 | 559 | 0.520 |
Why?
| | Immunoglobulin G | 3 | 2021 | 893 | 0.510 |
Why?
| | Health | 3 | 2017 | 81 | 0.500 |
Why?
| | Leuprolide | 2 | 2017 | 21 | 0.490 |
Why?
| | Abdomen | 9 | 2005 | 141 | 0.480 |
Why?
| | Hot Temperature | 1 | 2019 | 407 | 0.480 |
Why?
| | Blood Glucose | 22 | 2013 | 2330 | 0.480 |
Why?
| | Ibuprofen | 2 | 2021 | 84 | 0.470 |
Why?
| | Exercise Tolerance | 4 | 2025 | 283 | 0.460 |
Why?
| | Microdialysis | 7 | 2025 | 56 | 0.460 |
Why?
| | Dietary Supplements | 2 | 2017 | 576 | 0.460 |
Why?
| | Osteogenesis | 5 | 2020 | 208 | 0.460 |
Why?
| | Glucose Clamp Technique | 13 | 2014 | 199 | 0.460 |
Why?
| | Aged, 80 and over | 24 | 2019 | 8279 | 0.450 |
Why?
| | Glucose Tolerance Test | 12 | 2013 | 361 | 0.450 |
Why?
| | Medroxyprogesterone Acetate | 5 | 2003 | 37 | 0.450 |
Why?
| | Hypogonadism | 4 | 2024 | 90 | 0.450 |
Why?
| | Antibodies | 1 | 2017 | 403 | 0.440 |
Why?
| | Severity of Illness Index | 11 | 2018 | 2925 | 0.430 |
Why?
| | Selective Estrogen Receptor Modulators | 2 | 2017 | 36 | 0.430 |
Why?
| | Medroxyprogesterone | 2 | 2007 | 11 | 0.430 |
Why?
| | Young Adult | 21 | 2026 | 14126 | 0.420 |
Why?
| | Gonadal Steroid Hormones | 4 | 2021 | 144 | 0.420 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2025 | 34 | 0.420 |
Why?
| | Health Status | 4 | 2020 | 836 | 0.410 |
Why?
| | Perimenopause | 4 | 2022 | 66 | 0.410 |
Why?
| | Thigh | 3 | 2010 | 47 | 0.410 |
Why?
| | Body Weight | 14 | 2024 | 978 | 0.400 |
Why?
| | Running | 9 | 2015 | 228 | 0.390 |
Why?
| | Saliva | 2 | 2005 | 249 | 0.380 |
Why?
| | Femur | 6 | 2018 | 250 | 0.380 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 163 | 0.380 |
Why?
| | Deuterium | 6 | 2019 | 100 | 0.380 |
Why?
| | Cognition Disorders | 2 | 2015 | 538 | 0.370 |
Why?
| | Carotid Arteries | 6 | 2024 | 207 | 0.370 |
Why?
| | Sweat | 4 | 2019 | 51 | 0.360 |
Why?
| | Hydrocortisone | 3 | 2018 | 304 | 0.350 |
Why?
| | Heart-Assist Devices | 3 | 2023 | 567 | 0.340 |
Why?
| | Quality of Life | 8 | 2022 | 3192 | 0.340 |
Why?
| | Hormone Antagonists | 1 | 2011 | 34 | 0.340 |
Why?
| | Treatment Outcome | 18 | 2022 | 11695 | 0.340 |
Why?
| | Baroreflex | 2 | 2022 | 57 | 0.340 |
Why?
| | Adipose Tissue, Brown | 2 | 2024 | 60 | 0.340 |
Why?
| | Analysis of Variance | 11 | 2018 | 1311 | 0.340 |
Why?
| | Cognition | 3 | 2013 | 1269 | 0.330 |
Why?
| | Physical Education and Training | 14 | 1996 | 71 | 0.330 |
Why?
| | Procollagen | 3 | 2020 | 23 | 0.330 |
Why?
| | Osteocalcin | 5 | 2022 | 38 | 0.330 |
Why?
| | Hip | 6 | 2012 | 57 | 0.330 |
Why?
| | Body Mass Index | 10 | 2019 | 2438 | 0.320 |
Why?
| | Women's Health | 4 | 2024 | 310 | 0.320 |
Why?
| | Ovariectomy | 5 | 2025 | 162 | 0.320 |
Why?
| | Sympathetic Nervous System | 1 | 2011 | 178 | 0.310 |
Why?
| | Glucose Intolerance | 5 | 2001 | 142 | 0.310 |
Why?
| | Disability Evaluation | 5 | 2013 | 310 | 0.310 |
Why?
| | Acetaminophen | 1 | 2012 | 264 | 0.310 |
Why?
| | Vasodilator Agents | 1 | 2012 | 331 | 0.310 |
Why?
| | Gravitation | 1 | 2009 | 20 | 0.310 |
Why?
| | Bone Density Conservation Agents | 2 | 2024 | 81 | 0.310 |
Why?
| | HIV Infections | 8 | 2020 | 3154 | 0.300 |
Why?
| | Lipids | 6 | 2013 | 710 | 0.300 |
Why?
| | Sex Characteristics | 10 | 2024 | 791 | 0.300 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 100 | 0.300 |
Why?
| | Menstrual Cycle | 2 | 2013 | 140 | 0.300 |
Why?
| | Cross-Sectional Studies | 15 | 2026 | 5872 | 0.300 |
Why?
| | Alkaline Phosphatase | 3 | 2021 | 145 | 0.290 |
Why?
| | Osteoarthritis | 2 | 2015 | 196 | 0.290 |
Why?
| | Adolescent | 16 | 2026 | 22453 | 0.280 |
Why?
| | Heart Failure | 4 | 2024 | 2323 | 0.280 |
Why?
| | Progesterone Congeners | 3 | 2003 | 14 | 0.280 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1217 | 0.280 |
Why?
| | Physical Exertion | 6 | 2001 | 207 | 0.280 |
Why?
| | Dyslipidemias | 1 | 2010 | 182 | 0.280 |
Why?
| | Range of Motion, Articular | 7 | 2017 | 424 | 0.280 |
Why?
| | Oxidative Stress | 6 | 2026 | 1339 | 0.280 |
Why?
| | Case-Control Studies | 8 | 2025 | 3608 | 0.270 |
Why?
| | Hematopoietic Stem Cells | 4 | 2025 | 420 | 0.270 |
Why?
| | Urine | 3 | 2004 | 62 | 0.270 |
Why?
| | Pain Measurement | 6 | 2018 | 555 | 0.260 |
Why?
| | Prospective Studies | 16 | 2019 | 7997 | 0.260 |
Why?
| | Sports | 5 | 2020 | 211 | 0.260 |
Why?
| | Pain Threshold | 3 | 2018 | 73 | 0.260 |
Why?
| | High-Intensity Interval Training | 2 | 2018 | 46 | 0.250 |
Why?
| | Circadian Rhythm | 4 | 2020 | 514 | 0.250 |
Why?
| | Body Water | 2 | 2004 | 23 | 0.250 |
Why?
| | Peptide Fragments | 3 | 2020 | 699 | 0.250 |
Why?
| | Area Under Curve | 6 | 2013 | 331 | 0.250 |
Why?
| | Triglycerides | 4 | 2011 | 521 | 0.250 |
Why?
| | Fractures, Bone | 4 | 2016 | 415 | 0.240 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2019 | 3890 | 0.240 |
Why?
| | Postural Balance | 6 | 2015 | 240 | 0.230 |
Why?
| | Sirtuins | 1 | 2026 | 50 | 0.230 |
Why?
| | Risk Factors | 12 | 2019 | 10792 | 0.230 |
Why?
| | Radioisotope Dilution Technique | 2 | 2004 | 14 | 0.230 |
Why?
| | Heart Ventricles | 2 | 2020 | 760 | 0.230 |
Why?
| | Blood Coagulation | 1 | 2007 | 268 | 0.220 |
Why?
| | Cardiac Output | 5 | 2023 | 179 | 0.220 |
Why?
| | Water | 2 | 2019 | 469 | 0.220 |
Why?
| | Cholesterol | 4 | 2011 | 408 | 0.220 |
Why?
| | Basal Metabolism | 1 | 2005 | 63 | 0.220 |
Why?
| | Alendronate | 1 | 2024 | 14 | 0.220 |
Why?
| | Bone Marrow Cells | 3 | 2021 | 320 | 0.210 |
Why?
| | Diet | 8 | 2019 | 1275 | 0.210 |
Why?
| | Body Constitution | 2 | 2001 | 51 | 0.210 |
Why?
| | Cholesterol, HDL | 5 | 2011 | 200 | 0.210 |
Why?
| | Physical Conditioning, Animal | 5 | 2025 | 243 | 0.210 |
Why?
| | Serum | 1 | 2004 | 59 | 0.210 |
Why?
| | Time Factors | 14 | 2019 | 7183 | 0.210 |
Why?
| | Recovery of Function | 6 | 2017 | 710 | 0.210 |
Why?
| | Regression Analysis | 6 | 2011 | 1003 | 0.210 |
Why?
| | Blood Pressure | 10 | 2022 | 1769 | 0.200 |
Why?
| | Placebos | 4 | 2011 | 193 | 0.200 |
Why?
| | HIV-1 | 4 | 2013 | 896 | 0.200 |
Why?
| | Endothelin-1 | 1 | 2025 | 184 | 0.200 |
Why?
| | Caloric Restriction | 1 | 2024 | 127 | 0.190 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2024 | 162 | 0.190 |
Why?
| | Adipose Tissue, White | 2 | 2024 | 43 | 0.190 |
Why?
| | Sports Medicine | 1 | 2004 | 117 | 0.190 |
Why?
| | Cardiorespiratory Fitness | 2 | 2024 | 72 | 0.190 |
Why?
| | Rats, Wistar | 1 | 2024 | 451 | 0.190 |
Why?
| | Diet, Reducing | 2 | 2001 | 91 | 0.180 |
Why?
| | Arginine | 4 | 2017 | 262 | 0.180 |
Why?
| | Cold Temperature | 2 | 2024 | 209 | 0.180 |
Why?
| | Thermogenesis | 2 | 2024 | 45 | 0.180 |
Why?
| | Intermittent Claudication | 2 | 2015 | 121 | 0.180 |
Why?
| | Torque | 2 | 2012 | 81 | 0.180 |
Why?
| | Circadian Clocks | 2 | 2019 | 59 | 0.180 |
Why?
| | Insulin-Like Growth Factor I | 5 | 2013 | 319 | 0.170 |
Why?
| | Knee Joint | 6 | 2017 | 426 | 0.170 |
Why?
| | Oxygen Isotopes | 2 | 2019 | 24 | 0.170 |
Why?
| | Vitamin D | 3 | 2020 | 400 | 0.170 |
Why?
| | Ventricular Function, Right | 2 | 2020 | 297 | 0.170 |
Why?
| | Weight Reduction Programs | 2 | 2014 | 137 | 0.170 |
Why?
| | Ultrasonography | 7 | 2018 | 770 | 0.170 |
Why?
| | Proteins | 5 | 1998 | 1022 | 0.170 |
Why?
| | Pressoreceptors | 1 | 2021 | 19 | 0.170 |
Why?
| | Intestinal Absorption | 1 | 2001 | 103 | 0.170 |
Why?
| | Polysaccharides | 2 | 2021 | 87 | 0.160 |
Why?
| | Dexamethasone | 2 | 2018 | 372 | 0.160 |
Why?
| | Glycosylation | 2 | 2021 | 172 | 0.160 |
Why?
| | Postprandial Period | 1 | 2001 | 118 | 0.160 |
Why?
| | Muscle Proteins | 3 | 2019 | 244 | 0.160 |
Why?
| | Hip Joint | 3 | 2019 | 172 | 0.160 |
Why?
| | Pulmonary Gas Exchange | 5 | 2017 | 119 | 0.160 |
Why?
| | Cross-Over Studies | 3 | 2014 | 601 | 0.160 |
Why?
| | Lactates | 8 | 2012 | 83 | 0.160 |
Why?
| | Animals | 23 | 2025 | 38109 | 0.160 |
Why?
| | Interleukin-6 | 2 | 2022 | 780 | 0.160 |
Why?
| | Luteal Phase | 2 | 2014 | 46 | 0.160 |
Why?
| | Carbohydrate Metabolism | 3 | 1998 | 61 | 0.160 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2023 | 392 | 0.160 |
Why?
| | Age Factors | 7 | 2025 | 3335 | 0.150 |
Why?
| | Research Design | 4 | 2024 | 1137 | 0.150 |
Why?
| | Endothelial Cells | 1 | 2026 | 870 | 0.150 |
Why?
| | Oxidation-Reduction | 5 | 2020 | 1087 | 0.150 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 29 | 0.150 |
Why?
| | Reference Values | 6 | 2013 | 798 | 0.150 |
Why?
| | Pilot Projects | 6 | 2020 | 1890 | 0.150 |
Why?
| | Mitochondria | 1 | 2026 | 984 | 0.150 |
Why?
| | Myocardial Contraction | 1 | 2020 | 298 | 0.150 |
Why?
| | Coronary Disease | 2 | 2001 | 386 | 0.150 |
Why?
| | Surveys and Questionnaires | 8 | 2019 | 6053 | 0.150 |
Why?
| | Adjuvants, Immunologic | 1 | 2000 | 245 | 0.150 |
Why?
| | Patient Compliance | 4 | 2015 | 589 | 0.150 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2019 | 52 | 0.150 |
Why?
| | Cholesterol, LDL | 4 | 2011 | 358 | 0.140 |
Why?
| | Health Behavior | 1 | 2004 | 786 | 0.140 |
Why?
| | Calcium Channels, L-Type | 1 | 2019 | 118 | 0.140 |
Why?
| | Compliance | 2 | 2018 | 49 | 0.140 |
Why?
| | Homocysteine | 1 | 2019 | 151 | 0.140 |
Why?
| | Acidosis | 1 | 2019 | 105 | 0.140 |
Why?
| | Extracellular Fluid | 1 | 2018 | 37 | 0.140 |
Why?
| | Geographic Atrophy | 1 | 2019 | 97 | 0.140 |
Why?
| | Cortisone | 1 | 2018 | 16 | 0.140 |
Why?
| | Swimming | 2 | 1989 | 50 | 0.140 |
Why?
| | Proof of Concept Study | 1 | 2018 | 85 | 0.140 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2019 | 214 | 0.140 |
Why?
| | Ions | 1 | 2018 | 71 | 0.140 |
Why?
| | Cancellous Bone | 1 | 2017 | 22 | 0.130 |
Why?
| | Osteoarthritis, Hip | 1 | 2018 | 45 | 0.130 |
Why?
| | Obesity, Abdominal | 2 | 2017 | 46 | 0.130 |
Why?
| | Cysteine | 1 | 2019 | 210 | 0.130 |
Why?
| | omega-N-Methylarginine | 1 | 1997 | 29 | 0.130 |
Why?
| | Cardiovascular Physiological Phenomena | 3 | 2015 | 48 | 0.130 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2018 | 147 | 0.130 |
Why?
| | Macular Degeneration | 1 | 2019 | 191 | 0.130 |
Why?
| | Rest | 2 | 1997 | 124 | 0.130 |
Why?
| | Physical Therapy Modalities | 2 | 2012 | 332 | 0.130 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2020 | 248 | 0.130 |
Why?
| | Growth Hormone | 1 | 1997 | 92 | 0.130 |
Why?
| | Integrin beta1 | 1 | 2017 | 33 | 0.130 |
Why?
| | Isotope Labeling | 1 | 2017 | 83 | 0.130 |
Why?
| | Galactose | 1 | 2017 | 34 | 0.130 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2018 | 124 | 0.130 |
Why?
| | Luteinizing Hormone | 2 | 2015 | 190 | 0.130 |
Why?
| | Forearm | 1 | 1997 | 140 | 0.130 |
Why?
| | Hypokinesia | 1 | 2016 | 11 | 0.120 |
Why?
| | Healthy Volunteers | 2 | 2017 | 215 | 0.120 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2019 | 2584 | 0.120 |
Why?
| | Pelvic Bones | 1 | 2018 | 135 | 0.120 |
Why?
| | Gait Disorders, Neurologic | 1 | 2017 | 45 | 0.120 |
Why?
| | Osteoporotic Fractures | 1 | 2017 | 61 | 0.120 |
Why?
| | Hyperinsulinism | 3 | 2003 | 113 | 0.120 |
Why?
| | Lipid Metabolism | 3 | 1998 | 528 | 0.120 |
Why?
| | Vascular Diseases | 1 | 2019 | 251 | 0.120 |
Why?
| | Peripheral Arterial Disease | 2 | 2015 | 503 | 0.120 |
Why?
| | Electromyography | 2 | 2016 | 415 | 0.120 |
Why?
| | Food, Fortified | 1 | 2016 | 44 | 0.120 |
Why?
| | Administration, Cutaneous | 3 | 2015 | 125 | 0.120 |
Why?
| | Mice | 8 | 2025 | 18365 | 0.120 |
Why?
| | Pain | 1 | 2001 | 782 | 0.120 |
Why?
| | Stroke Volume | 6 | 2023 | 651 | 0.120 |
Why?
| | Adipocytes, White | 1 | 2015 | 18 | 0.120 |
Why?
| | Energy Intake | 5 | 2013 | 500 | 0.120 |
Why?
| | Gonadotropins | 1 | 2015 | 39 | 0.120 |
Why?
| | Nitric Oxide | 2 | 2017 | 897 | 0.110 |
Why?
| | Muscle Strength Dynamometer | 2 | 2012 | 23 | 0.110 |
Why?
| | Aging, Premature | 2 | 2013 | 16 | 0.110 |
Why?
| | Predictive Value of Tests | 4 | 2015 | 2118 | 0.110 |
Why?
| | Injections, Intravenous | 2 | 2006 | 200 | 0.110 |
Why?
| | Muscles | 7 | 2013 | 333 | 0.110 |
Why?
| | Wrist Joint | 1 | 1995 | 71 | 0.110 |
Why?
| | Stem Cells | 2 | 2017 | 627 | 0.110 |
Why?
| | Precision Medicine | 1 | 2019 | 458 | 0.110 |
Why?
| | Metabolomics | 1 | 2020 | 727 | 0.110 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2012 | 192 | 0.100 |
Why?
| | Linear Models | 2 | 2008 | 854 | 0.100 |
Why?
| | Mass Spectrometry | 1 | 2017 | 750 | 0.100 |
Why?
| | Clinical Trials as Topic | 4 | 2016 | 1054 | 0.100 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5997 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 2032 | 0.100 |
Why?
| | Accidental Falls | 2 | 2017 | 222 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 3 | 2014 | 2738 | 0.100 |
Why?
| | Etanercept | 1 | 2013 | 60 | 0.100 |
Why?
| | Catecholamines | 1 | 1993 | 87 | 0.100 |
Why?
| | Anti-HIV Agents | 4 | 2014 | 888 | 0.100 |
Why?
| | Neck Pain | 1 | 2013 | 30 | 0.100 |
Why?
| | Spine | 1 | 1995 | 182 | 0.100 |
Why?
| | Health Status Indicators | 2 | 2011 | 166 | 0.100 |
Why?
| | Radiography | 2 | 2012 | 845 | 0.100 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 134 | 0.100 |
Why?
| | Community Health Services | 1 | 2015 | 234 | 0.100 |
Why?
| | Life Style | 3 | 2008 | 479 | 0.100 |
Why?
| | C-Reactive Protein | 2 | 2022 | 417 | 0.100 |
Why?
| | Longitudinal Studies | 4 | 2018 | 2947 | 0.100 |
Why?
| | Anti-Retroviral Agents | 1 | 2015 | 250 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2018 | 5417 | 0.090 |
Why?
| | Superoxide Dismutase | 1 | 2015 | 301 | 0.090 |
Why?
| | Microfluidics | 1 | 2013 | 62 | 0.090 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2013 | 51 | 0.090 |
Why?
| | Acupressure | 1 | 2012 | 9 | 0.090 |
Why?
| | Mathematical Concepts | 1 | 2013 | 36 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2005 | 1990 | 0.090 |
Why?
| | Hunger | 1 | 2013 | 57 | 0.090 |
Why?
| | Femoral Neck Fractures | 1 | 2012 | 21 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 1048 | 0.090 |
Why?
| | Steroids | 1 | 2013 | 160 | 0.090 |
Why?
| | Myofascial Pain Syndromes | 1 | 2012 | 12 | 0.090 |
Why?
| | Carbon Isotopes | 2 | 2006 | 144 | 0.090 |
Why?
| | Posture | 1 | 1993 | 196 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2012 | 73 | 0.090 |
Why?
| | Receptors, CCR5 | 1 | 2012 | 60 | 0.090 |
Why?
| | Cervix Uteri | 1 | 2012 | 50 | 0.090 |
Why?
| | Hemodynamics | 4 | 2023 | 1121 | 0.090 |
Why?
| | Neuropsychological Tests | 2 | 2015 | 1137 | 0.090 |
Why?
| | Sarcopenia | 1 | 2013 | 91 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 250 | 0.090 |
Why?
| | HIV Seropositivity | 1 | 2012 | 119 | 0.090 |
Why?
| | Hysterectomy | 1 | 2012 | 138 | 0.090 |
Why?
| | Incidence | 3 | 2019 | 2883 | 0.090 |
Why?
| | Meals | 1 | 2013 | 130 | 0.090 |
Why?
| | Gait | 4 | 2015 | 313 | 0.090 |
Why?
| | Oxytocics | 1 | 2011 | 15 | 0.090 |
Why?
| | Headache | 1 | 2012 | 150 | 0.090 |
Why?
| | Chromatography, Liquid | 1 | 2013 | 454 | 0.090 |
Why?
| | Muscle Fatigue | 1 | 2012 | 97 | 0.080 |
Why?
| | Fatty Acids, Nonesterified | 5 | 2001 | 158 | 0.080 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2012 | 235 | 0.080 |
Why?
| | Cartilage, Articular | 1 | 2015 | 343 | 0.080 |
Why?
| | Kinetics | 5 | 2003 | 1629 | 0.080 |
Why?
| | Longevity | 2 | 2024 | 173 | 0.080 |
Why?
| | Combined Modality Therapy | 3 | 2013 | 1268 | 0.080 |
Why?
| | Dinoprostone | 1 | 2011 | 178 | 0.080 |
Why?
| | Perception | 2 | 2013 | 377 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 529 | 0.080 |
Why?
| | Athletes | 1 | 2014 | 419 | 0.080 |
Why?
| | Single-Blind Method | 3 | 2016 | 312 | 0.080 |
Why?
| | Parity | 1 | 2010 | 109 | 0.080 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 577 | 0.080 |
Why?
| | Contraceptive Agents | 1 | 2010 | 65 | 0.080 |
Why?
| | Cohort Studies | 2 | 2012 | 5965 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 1999 | 1389 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2022 | 433 | 0.070 |
Why?
| | Androgens | 2 | 2017 | 186 | 0.070 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 842 | 0.070 |
Why?
| | Antiparkinson Agents | 2 | 2022 | 41 | 0.070 |
Why?
| | Efficiency | 1 | 1989 | 104 | 0.070 |
Why?
| | Bone Diseases, Metabolic | 2 | 2019 | 56 | 0.070 |
Why?
| | Respiration | 4 | 2015 | 207 | 0.070 |
Why?
| | Carbon Dioxide | 2 | 2010 | 242 | 0.070 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2013 | 1129 | 0.070 |
Why?
| | Chronic Pain | 1 | 2013 | 292 | 0.070 |
Why?
| | Muscle Contraction | 1 | 2011 | 429 | 0.070 |
Why?
| | Rats | 8 | 2024 | 5614 | 0.070 |
Why?
| | Depression | 1 | 2018 | 1559 | 0.070 |
Why?
| | Statistics as Topic | 1 | 2009 | 284 | 0.070 |
Why?
| | Calcium Citrate | 1 | 2008 | 1 | 0.070 |
Why?
| | Advance Care Planning | 1 | 2012 | 243 | 0.070 |
Why?
| | Mechanotransduction, Cellular | 1 | 2009 | 122 | 0.070 |
Why?
| | Executive Function | 1 | 2013 | 461 | 0.070 |
Why?
| | Spectrum Analysis | 2 | 2019 | 93 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 783 | 0.070 |
Why?
| | Cytokines | 1 | 2015 | 2065 | 0.070 |
Why?
| | Dietary Fats | 4 | 2013 | 315 | 0.070 |
Why?
| | Ventricular Function, Left | 3 | 2023 | 541 | 0.060 |
Why?
| | Low Back Pain | 1 | 2008 | 107 | 0.060 |
Why?
| | Norepinephrine | 2 | 2021 | 196 | 0.060 |
Why?
| | Leg | 3 | 2002 | 239 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1540 | 0.060 |
Why?
| | Carrier Proteins | 2 | 2005 | 737 | 0.060 |
Why?
| | Electric Stimulation | 1 | 2007 | 276 | 0.060 |
Why?
| | Cell Differentiation | 3 | 2021 | 2050 | 0.060 |
Why?
| | Risk Reduction Behavior | 1 | 2008 | 226 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1496 | 0.060 |
Why?
| | Glycoproteins | 2 | 2021 | 355 | 0.060 |
Why?
| | Densitometry | 2 | 1998 | 38 | 0.060 |
Why?
| | Radioimmunoassay | 1 | 2005 | 165 | 0.060 |
Why?
| | Buttocks | 1 | 2005 | 14 | 0.060 |
Why?
| | Immunoenzyme Techniques | 1 | 2005 | 200 | 0.060 |
Why?
| | Follicular Phase | 1 | 2005 | 38 | 0.060 |
Why?
| | Blood Coagulation Disorders | 1 | 2007 | 189 | 0.050 |
Why?
| | Cell Lineage | 2 | 2017 | 376 | 0.050 |
Why?
| | Nutritional Status | 2 | 2019 | 354 | 0.050 |
Why?
| | Calorimetry, Indirect | 2 | 2017 | 83 | 0.050 |
Why?
| | Colorado | 4 | 2019 | 4564 | 0.050 |
Why?
| | Logistic Models | 2 | 2019 | 2119 | 0.050 |
Why?
| | Administration, Oral | 2 | 2018 | 848 | 0.050 |
Why?
| | Pulse Wave Analysis | 1 | 2024 | 266 | 0.050 |
Why?
| | Plethysmography | 2 | 2022 | 109 | 0.050 |
Why?
| | Endometrium | 1 | 2003 | 61 | 0.050 |
Why?
| | Models, Animal | 1 | 2004 | 392 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2015 | 427 | 0.050 |
Why?
| | ADP-ribosyl Cyclase 1 | 2 | 2013 | 43 | 0.050 |
Why?
| | Liver | 3 | 2024 | 1888 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 2 | 2013 | 277 | 0.050 |
Why?
| | Skinfold Thickness | 2 | 1992 | 43 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 117 | 0.050 |
Why?
| | Disease Progression | 1 | 2010 | 2852 | 0.050 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2022 | 59 | 0.050 |
Why?
| | Retrospective Studies | 5 | 2019 | 17101 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2024 | 343 | 0.040 |
Why?
| | Diphtheria Toxin | 1 | 2022 | 65 | 0.040 |
Why?
| | Preoperative Period | 2 | 2014 | 149 | 0.040 |
Why?
| | Food Deprivation | 2 | 2000 | 27 | 0.040 |
Why?
| | Osteocytes | 1 | 2001 | 24 | 0.040 |
Why?
| | Knee | 2 | 1997 | 71 | 0.040 |
Why?
| | Eating | 2 | 2001 | 392 | 0.040 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2022 | 148 | 0.040 |
Why?
| | Lipoproteins | 2 | 2000 | 169 | 0.040 |
Why?
| | Postoperative Period | 2 | 2014 | 354 | 0.040 |
Why?
| | Movement | 2 | 2014 | 294 | 0.040 |
Why?
| | Survival Analysis | 2 | 2015 | 1385 | 0.040 |
Why?
| | Hyperlipidemias | 1 | 2002 | 122 | 0.040 |
Why?
| | Ultrasonography, Doppler | 1 | 2022 | 126 | 0.040 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 10 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2005 | 535 | 0.040 |
Why?
| | Tibia | 2 | 2019 | 176 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 405 | 0.040 |
Why?
| | Signal Transduction | 2 | 2021 | 5233 | 0.040 |
Why?
| | Stress, Mechanical | 2 | 2001 | 494 | 0.040 |
Why?
| | Musculoskeletal Physiological Phenomena | 1 | 2000 | 8 | 0.040 |
Why?
| | Respiratory Mechanics | 1 | 2000 | 72 | 0.040 |
Why?
| | Adiponectin | 1 | 2022 | 244 | 0.040 |
Why?
| | Blood Flow Velocity | 1 | 2022 | 413 | 0.040 |
Why?
| | Kidney | 2 | 1998 | 1496 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2020 | 174 | 0.040 |
Why?
| | Mice, Transgenic | 2 | 2015 | 2185 | 0.040 |
Why?
| | Electric Conductivity | 1 | 2019 | 84 | 0.040 |
Why?
| | Child Development | 1 | 1985 | 484 | 0.040 |
Why?
| | Blood Circulation | 1 | 1999 | 44 | 0.040 |
Why?
| | Fasting | 1 | 2001 | 277 | 0.040 |
Why?
| | Orchiectomy | 1 | 2019 | 74 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 99 | 0.040 |
Why?
| | Hand Strength | 1 | 2000 | 144 | 0.040 |
Why?
| | Electrocardiography | 2 | 2020 | 663 | 0.040 |
Why?
| | Anthropometry | 2 | 2017 | 200 | 0.040 |
Why?
| | Muscle Development | 1 | 2000 | 116 | 0.040 |
Why?
| | Physician's Role | 1 | 2001 | 220 | 0.040 |
Why?
| | Radius | 1 | 2019 | 52 | 0.040 |
Why?
| | Collagen | 1 | 2001 | 456 | 0.040 |
Why?
| | Attitude | 1 | 2001 | 261 | 0.040 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 39 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2020 | 221 | 0.040 |
Why?
| | Antioxidants | 1 | 2022 | 549 | 0.040 |
Why?
| | Actigraphy | 1 | 2019 | 145 | 0.030 |
Why?
| | Injections, Intra-Articular | 1 | 2018 | 58 | 0.030 |
Why?
| | North Carolina | 1 | 2018 | 128 | 0.030 |
Why?
| | Isometric Contraction | 2 | 2010 | 188 | 0.030 |
Why?
| | Administration, Topical | 1 | 2018 | 150 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2013 | 1327 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2019 | 138 | 0.030 |
Why?
| | Conservative Treatment | 1 | 2018 | 44 | 0.030 |
Why?
| | Ventricular Remodeling | 1 | 2000 | 276 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2015 | 1095 | 0.030 |
Why?
| | Estrogen Receptor alpha | 1 | 2019 | 161 | 0.030 |
Why?
| | Nephrectomy | 1 | 1998 | 158 | 0.030 |
Why?
| | Mental Health | 2 | 2015 | 792 | 0.030 |
Why?
| | Hamstring Muscles | 1 | 2017 | 22 | 0.030 |
Why?
| | Goserelin | 1 | 2017 | 8 | 0.030 |
Why?
| | Transcriptome | 1 | 2024 | 1046 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 428 | 0.030 |
Why?
| | Fertility Agents, Female | 1 | 2017 | 21 | 0.030 |
Why?
| | Pregnancy | 1 | 2010 | 7191 | 0.030 |
Why?
| | Blood | 2 | 1995 | 109 | 0.030 |
Why?
| | Psychometrics | 1 | 2001 | 734 | 0.030 |
Why?
| | Blood Chemical Analysis | 1 | 1997 | 109 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 560 | 0.030 |
Why?
| | Adipogenesis | 1 | 2017 | 57 | 0.030 |
Why?
| | Cell Size | 1 | 1996 | 92 | 0.030 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 75 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 1989 | 3869 | 0.030 |
Why?
| | Joints | 1 | 1997 | 107 | 0.030 |
Why?
| | Fibrin | 1 | 2017 | 91 | 0.030 |
Why?
| | Heart | 1 | 2020 | 636 | 0.030 |
Why?
| | Accelerometry | 1 | 2017 | 119 | 0.030 |
Why?
| | Glycogen | 1 | 1996 | 54 | 0.030 |
Why?
| | Cell Fusion | 1 | 2015 | 49 | 0.030 |
Why?
| | Child | 3 | 2024 | 22657 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2017 | 148 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 1998 | 268 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2018 | 266 | 0.030 |
Why?
| | Monosaccharide Transport Proteins | 1 | 1996 | 56 | 0.030 |
Why?
| | Affect | 1 | 2018 | 318 | 0.030 |
Why?
| | Mental Status Schedule | 1 | 2015 | 35 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2882 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 20 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1995 | 166 | 0.030 |
Why?
| | Fatty Acids | 1 | 1998 | 452 | 0.030 |
Why?
| | Calibration | 1 | 1995 | 151 | 0.030 |
Why?
| | Neurophysiology | 1 | 2015 | 13 | 0.030 |
Why?
| | Databases, Bibliographic | 1 | 2015 | 30 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 80 | 0.030 |
Why?
| | Capillaries | 1 | 1996 | 124 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1998 | 339 | 0.030 |
Why?
| | Muscular Atrophy | 1 | 1995 | 89 | 0.030 |
Why?
| | Arthrometry, Articular | 1 | 2014 | 9 | 0.030 |
Why?
| | Models, Statistical | 1 | 2019 | 682 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 873 | 0.030 |
Why?
| | Alzheimer Disease | 1 | 2001 | 622 | 0.030 |
Why?
| | Progesterone | 1 | 2015 | 255 | 0.030 |
Why?
| | Cholesterol Esters | 1 | 1993 | 7 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2007 | 3415 | 0.030 |
Why?
| | Models, Biological | 2 | 1999 | 1822 | 0.020 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 32 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2018 | 603 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2013 | 45 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2015 | 282 | 0.020 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 20 | 0.020 |
Why?
| | Citrates | 1 | 1993 | 41 | 0.020 |
Why?
| | Calorimetry | 1 | 2013 | 72 | 0.020 |
Why?
| | Anaerobic Threshold | 1 | 1992 | 28 | 0.020 |
Why?
| | Epinephrine | 1 | 1993 | 155 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 2014 | 180 | 0.020 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 179 | 0.020 |
Why?
| | Comorbidity | 1 | 1998 | 1660 | 0.020 |
Why?
| | Patient Dropouts | 1 | 2013 | 65 | 0.020 |
Why?
| | Appetite | 1 | 2013 | 69 | 0.020 |
Why?
| | United States | 1 | 2010 | 15988 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2836 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2013 | 151 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2015 | 612 | 0.020 |
Why?
| | Blood Loss, Surgical | 1 | 2012 | 112 | 0.020 |
Why?
| | Somatomedins | 1 | 1991 | 28 | 0.020 |
Why?
| | Upper Extremity | 1 | 2013 | 112 | 0.020 |
Why?
| | Dietary Proteins | 1 | 2013 | 136 | 0.020 |
Why?
| | Apolipoproteins B | 1 | 1991 | 47 | 0.020 |
Why?
| | Counseling | 1 | 2015 | 408 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 333 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 278 | 0.020 |
Why?
| | Hypertension | 1 | 2000 | 1264 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2013 | 233 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2017 | 676 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2012 | 220 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1258 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2011 | 62 | 0.020 |
Why?
| | Registries | 1 | 2019 | 2385 | 0.020 |
Why?
| | Viral Load | 1 | 2013 | 526 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 949 | 0.020 |
Why?
| | Glycogen Storage Disease Type V | 1 | 1990 | 1 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 496 | 0.020 |
Why?
| | Physical Phenomena | 1 | 2010 | 13 | 0.020 |
Why?
| | Computational Biology | 1 | 2015 | 681 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 348 | 0.020 |
Why?
| | Hyperglycemia | 2 | 1991 | 375 | 0.020 |
Why?
| | Blood Vessels | 1 | 1991 | 171 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2609 | 0.020 |
Why?
| | Odds Ratio | 1 | 2012 | 1077 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4155 | 0.020 |
Why?
| | Spirometry | 1 | 2010 | 231 | 0.020 |
Why?
| | Macrophages | 1 | 2017 | 1511 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1126 | 0.020 |
Why?
| | Body Temperature | 1 | 2010 | 229 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1054 | 0.020 |
Why?
| | Overweight | 1 | 2014 | 609 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 3 | 2000 | 2540 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3676 | 0.020 |
Why?
| | Pain Management | 1 | 2012 | 405 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2010 | 547 | 0.020 |
Why?
| | Iodine Radioisotopes | 2 | 1998 | 137 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2008 | 255 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2013 | 4569 | 0.020 |
Why?
| | Respiratory Muscles | 1 | 1987 | 36 | 0.020 |
Why?
| | Body Fluids | 1 | 1987 | 70 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 917 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 198 | 0.010 |
Why?
| | Prognosis | 1 | 2014 | 4293 | 0.010 |
Why?
| | Aerobiosis | 1 | 1985 | 22 | 0.010 |
Why?
| | Neoplasms | 1 | 2001 | 2884 | 0.010 |
Why?
| | Shoes | 1 | 1985 | 18 | 0.010 |
Why?
| | DNA | 1 | 2012 | 1464 | 0.010 |
Why?
| | Orthotic Devices | 1 | 1985 | 26 | 0.010 |
Why?
| | Endometrial Hyperplasia | 1 | 2003 | 7 | 0.010 |
Why?
| | Body Height | 1 | 1985 | 202 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 2008 | 780 | 0.010 |
Why?
| | Uterine Hemorrhage | 1 | 2003 | 41 | 0.010 |
Why?
| | Inflammation | 1 | 2013 | 2880 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2004 | 328 | 0.010 |
Why?
| | Vascular Resistance | 2 | 1993 | 367 | 0.010 |
Why?
| | Matched-Pair Analysis | 1 | 2000 | 37 | 0.010 |
Why?
| | Infusions, Intravenous | 2 | 1991 | 423 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2012 | 2920 | 0.010 |
Why?
| | Biopsy | 1 | 2003 | 1077 | 0.010 |
Why?
| | Isoflavones | 1 | 1999 | 26 | 0.010 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2000 | 124 | 0.010 |
Why?
| | Hindlimb | 1 | 2000 | 131 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 1999 | 125 | 0.010 |
Why?
| | Vibration | 1 | 1999 | 71 | 0.010 |
Why?
| | Organ Size | 1 | 2000 | 463 | 0.010 |
Why?
| | Elasticity | 1 | 1999 | 184 | 0.010 |
Why?
| | Uterus | 1 | 2000 | 226 | 0.010 |
Why?
| | Acoustic Stimulation | 1 | 1999 | 334 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1997 | 115 | 0.010 |
Why?
| | Analgesics | 1 | 1999 | 231 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1997 | 334 | 0.010 |
Why?
| | Creatinine | 1 | 1998 | 506 | 0.010 |
Why?
| | Glucose Transporter Type 4 | 1 | 1996 | 38 | 0.010 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 1993 | 22 | 0.010 |
Why?
| | Citric Acid | 1 | 1993 | 34 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1993 | 167 | 0.010 |
Why?
| | Citrate (si)-Synthase | 1 | 1992 | 57 | 0.010 |
Why?
| | Breath Tests | 1 | 1992 | 79 | 0.010 |
Why?
| | Cell Membrane | 1 | 1996 | 706 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1991 | 69 | 0.010 |
Why?
| | Hormones | 1 | 1992 | 134 | 0.010 |
Why?
| | Mitochondria, Muscle | 1 | 1992 | 121 | 0.010 |
Why?
| | Glucosephosphates | 1 | 1990 | 3 | 0.010 |
Why?
| | Glucose-6-Phosphate | 1 | 1990 | 6 | 0.010 |
Why?
| | Hypercholesterolemia | 1 | 1991 | 93 | 0.010 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 1990 | 13 | 0.010 |
Why?
| | Lipoproteins, HDL2 | 1 | 1990 | 2 | 0.000 |
Why?
| | C-Peptide | 1 | 1991 | 189 | 0.000 |
Why?
| | Lipoproteins, HDL | 1 | 1990 | 101 | 0.000 |
Why?
| | Heart Diseases | 1 | 1993 | 350 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1990 | 561 | 0.000 |
Why?
| | Fatigue | 1 | 1991 | 366 | 0.000 |
Why?
| | Erythrocyte Volume | 1 | 1987 | 6 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1987 | 9 | 0.000 |
Why?
| | Plasma Volume | 1 | 1987 | 20 | 0.000 |
Why?
| | Oxygen | 1 | 1985 | 995 | 0.000 |
Why?
|
|
Kohrt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|